Efficacia e tollerabilità a lungo termine del topiramato come terapia aggiuntiva in pazienti con epilessia parziale farmacoresistente

Translated title of the contribution: Long-term evaluation of the efficacy and tolerability of topiramate as add-on therapy in patients with refractory partial epilepsy

A. La Neve, G. Boero, N. Specchio, G. De Agazio, A. De Paio, L. M. Specchio

Research output: Contribution to journalArticle

Abstract

TPM add-on long-term open-label treatment was evaluated in 76 patients with Partial Refractory Epilepsy over a mean period of 12 months. The mean TPM dosage was 418+168 mg/day. About 30% of patients achieved >50% seizure reduction; 10% of patients were seizure-free. 13 (15%) patients discontinued TPM because of adverse events. Findings from this study show that TPM is ah useful agent for long-term seizure control, with some patients becoming seizure-free.

Translated title of the contributionLong-term evaluation of the efficacy and tolerability of topiramate as add-on therapy in patients with refractory partial epilepsy
Original languageItalian
Pages (from-to)83-84
Number of pages2
JournalBollettino - Lega Italiana contro l'Epilessia
Issue number113-114
Publication statusPublished - 2001

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Long-term evaluation of the efficacy and tolerability of topiramate as add-on therapy in patients with refractory partial epilepsy'. Together they form a unique fingerprint.

Cite this